^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    TNFRSF19 (TNF Receptor Superfamily Member 19)

    i
    Other names: TNFRSF19, TNF Receptor Superfamily Member 19, TRADE, TROY, TAJ, Toxicity And JNK Inducer, TAJ-Alpha, Tumor Necrosis Factor Receptor Superfamily Member 19, Tumor Necrosis Factor Receptor Superfamily, Member 19
    Associations

    News

    Trials
    3d
    Application of interpretable machine learning to analyze DNA methylation sites in the progression from oral Leukoplakia to oral squamous cell carcinoma. (PubMed, Integr Biol (Camb))
    These multi-layered analyses provide novel insights into epigenetic mechanisms underlying OL to OSCC progression and highlight candidate biomarkers with strong translational potential. By combining IML based methylation modeling with external and cross-omics validation, this study advances the development of reliable, interpretable biomarkers for precision oral cancer diagnostics and management.
    Journal
    |
    TNFRSF9 (TNF Receptor Superfamily Member 9) • FOXP1 (Forkhead Box P1) • SH3PXD2A (SH3 And PX Domains 2A) • TNFRSF19 (TNF Receptor Superfamily Member 19)
    18d
    Recent advances in non-alcoholic steatohepatitis-associated hepatocellular carcinoma: immune cells, metabolic dysregulation, and therapeutic strategies. (PubMed, Front Oncol)
    Future directions emphasize novel immune targets (MDSCs, SLAMF1), metabolic reprogramming, and microbiota modulation for precision therapies. Integrating multimodal approaches holds promise for halting NASH-to-HCC progression and improving outcomes.
    Review • Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • HIF1A (Hypoxia inducible factor 1, alpha subunit) • TNFRSF9 (TNF Receptor Superfamily Member 9) • TGFB1 (Transforming Growth Factor Beta 1) • IL1B (Interleukin 1, beta) • PPARA (Peroxisome Proliferator Activated Receptor Alpha) • TNFRSF19 (TNF Receptor Superfamily Member 19)
    3ms
    Integration of genetic, proteomic, and transcriptomic data identifies therapeutic targets and prognostic biomarkers in bladder cancer. (PubMed, Transl Androl Urol)
    Methylation analyses indicated complex regulation of CTSS and TNFRSF19. WFDC1, RHOC, and GSTM4 exhibit therapeutic potential, while MFGE8, CTSS, TNFRSF19, and IL1RAP predict risk and prognosis, providing insights for precision diagnosis and treatment.
    Journal
    |
    ROR1 (Receptor Tyrosine Kinase Like Orphan Receptor 1) • TNFRSF9 (TNF Receptor Superfamily Member 9) • CTSS (Cathepsin S) • IL1RAP (Interleukin 1 Receptor Accessory Protein) • CD59 (CD59 Molecule) • TNFRSF19 (TNF Receptor Superfamily Member 19)
    3ms
    HSC-derived exosomal miR-122-5p inhibits EMT and fibrosis of intrahepatic biliary epithelial cells to alleviate primary biliary cholangitis. (PubMed, Front Immunol)
    In vivo results indicated that the degrees of inflammatory infiltration and fibrosis in liver tissues of both PBC patients and model mice were more severe than those of normal controls and were then alleviated with exosomal miR-122-5p treatment. In conclusion, exosomal miR-122-5p alleviates liver pathology in PBC by targeting the TNFRSF19/ASK1/p38 MAPK axis, highlighting its potential as both a diagnostic biomarker and a therapeutic target for PBC.
    Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • TNFRSF9 (TNF Receptor Superfamily Member 9) • MIR122 (MicroRNA 122) • TNFRSF19 (TNF Receptor Superfamily Member 19)
    6ms
    Circulating proteins and bone mineral density: A Proteome-Wide Mendelian Randomization Study. (PubMed, Curr Med Chem)
    This large-scale Proteome-Wide MR study introduced novel targets for BMD and osteoporosis at transcriptional and translational levels, presenting new prospects for drug repurposing and development.
    Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • TNFRSF9 (TNF Receptor Superfamily Member 9) • LYN (LYN Proto-Oncogene Src Family Tyrosine Kinase) • RSPO3 (R-Spondin 3) • TGFBI (Transforming Growth Factor Beta Induced) • RSPO1 (R-Spondin 1) • TNFRSF19 (TNF Receptor Superfamily Member 19)
    6ms
    Breakdown of blood-brain barrier, astrocytic endfeet swelling, and abnormal behaviors by blockade of TROY signaling in TROY-Fc transgenic mice. (PubMed, Brain Behav Immun)
    Behavioral tests revealed that TROY-Fc Tg mice exhibited a reduction in exploratory motivation and an enhancement of responses to stress. Thus, the signaling mediated by unidentified TROY ligand(s)-TROY interaction may be essential for proper neuronal function through the maintenance of intact BBB.
    Preclinical • Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • TNFRSF9 (TNF Receptor Superfamily Member 9) • TJP1 (Tight Junction Protein 1) • AQP4 (Aquaporin 4) • CLDN5 (Claudin 5) • OCLN (Occludin) • TNFRSF19 (TNF Receptor Superfamily Member 19)
    9ms
    CircTNFRSF19 Facilitates Triple Negative Breast Cancer Cell Growth by Regulating N6-methyladenosine Modification of B3GNT5: Medical biological image simulation. (PubMed, SLAS Technol)
    CRISPR/Cas9 gene editing experiments showed that after CircTNFRSF19 was knocked out, the m6A modification level of B3GNT5 was significantly decreased, and the growth rate of TNBC cells was also significantly slowed down. The application of medical thermal image simulation technology revealed that the metabolic activity of the cells in the CircTNFRSF19 knockout group was reduced, and the temperature change of the cell growth area was significantly different from that in the control group.
    Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • TNFRSF9 (TNF Receptor Superfamily Member 9) • TNFRSF19 (TNF Receptor Superfamily Member 19)
    over1year
    LncRNA ZFPM2-AS1 promotes phyllodes tumor progression by binding to CDC42 and inhibiting STAT1 activation. (PubMed, Acta Pharm Sin B)
    Mechanistically, our findings showed that ZFPM2-AS1 is competitively bound to CDC42, inhibiting ACK1 and STAT1 activation, thereby launching the transcription of TNFRSF19. In conclusion, our study provides evidence that ZFPM2-AS1 plays a pivotal role in the pathogenesis of breast PT, and suggests that ZFPM2-AS1 could serve as a prognostic indicator for patients with PT as well as a promising novel therapeutic target.
    Journal
    |
    TNFRSF9 (TNF Receptor Superfamily Member 9) • STAT1 (Signal Transducer And Activator Of Transcription 1) • TNFRSF19 (TNF Receptor Superfamily Member 19)
    over1year
    Cancer-associated fibroblasts (CAFs) gene signatures predict outcomes in breast and prostate tumor patients. (PubMed, J Transl Med)
    We identified a huge heterogeneity in the transcriptional profile of CAFs derived from breast and prostate tumors. Of note, the two novel CAFs-related gene signatures might be considered as reliable prognostic indicators and valuable biomarkers for a better management of breast and prostate cancer patients.
    Journal • Gene Signature
    |
    SPP1 (Secreted Phosphoprotein 1) • TNFRSF9 (TNF Receptor Superfamily Member 9) • LIFR (LIF Receptor Subunit Alpha) • IL13RA2 (Interleukin 13 Receptor Subunit Alpha 2) • CD40LG (CD40 ligand) • CXCL5 (Chemokine (C-X-C motif) ligand 5) • CXCL6 (C-X-C Motif Chemokine Ligand 6) • IL7 (Interleukin 7) • TSLP (Thymic Stromal Lymphopoietin) • CXCL1 (Chemokine (C-X-C motif) ligand 1) • IL33 (Interleukin 33) • ITGA1 (Integrin Subunit Alpha 1) • ITGA2 (Integrin Subunit Alpha 2) • TNFRSF19 (TNF Receptor Superfamily Member 19)
    almost2years
    First Transcriptome Analysis of Hepatoblastoma in Brazil: Unraveling the Pivotal Role of Noncoding RNAs and Metabolic Pathways. (PubMed, Biochem Genet)
    In summary, our transcriptome analysis highlighted disrupted embryonic development as well as metabolic pathways, particularly those involving lipids, emphasizing the emerging role of ncRNAs as epigenetic regulators in hepatoblastomas. These findings provide insights into the complexity of the hepatoblastoma transcriptome and identify potential targets for future therapeutic interventions.
    Journal • Tumor mutational burden
    |
    TMB (Tumor Mutational Burden) • CCND1 (Cyclin D1) • DKK1 (dickkopf WNT signaling pathway inhibitor 1) • TNFRSF9 (TNF Receptor Superfamily Member 9) • HDAC2 (Histone deacetylase 2) • DKK4 (Dickkopf WNT Signaling Pathway Inhibitor 4) • HMGA2 (High mobility group AT-hook 2) • CDH3 (Cadherin 3) • MIR186 (MicroRNA 186) • MIR494 (MicroRNA 494) • MEG3 (Maternally Expressed 3) • MIR214 (MicroRNA 214) • TNFRSF19 (TNF Receptor Superfamily Member 19)
    |
    TMB-L
    almost2years
    Association of TNFRSF19 with a TNF family-based prognostic model and subtypes in gliomas using machine learning. (PubMed, Heliyon)
    The TMF-based prognostic model and subtype can facilitate treatment decisions for glioma. TNFRSF19 is an outstanding representative of a predictor of prognosis and immunotherapy effect in gliomas.
    Journal • IO biomarker • Machine learning
    |
    TNFRSF9 (TNF Receptor Superfamily Member 9) • TNFRSF19 (TNF Receptor Superfamily Member 19)
    2years
    ANKRD2 expression combined with TNFRSF19 expression for evaluating the prognosis of oral squamous cell carcinoma patients. (PubMed, Heliyon)
    ANKRD2 and TNFRSF19 may be targets for cisplatin sensitivity prediction in OSCC patients. These findings may provide novel strategies for overcoming cisplatin resistance.
    Journal
    |
    TNFRSF9 (TNF Receptor Superfamily Member 9) • TNFRSF19 (TNF Receptor Superfamily Member 19)
    |
    cisplatin